Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 95Breast Neoplasms, Male 6Advanced Breast Cancer 4Triple Negative Breast Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Infertility 2Sexual Dysfunctions, Psychological 1Primary Ovarian Insufficiency 1Patient Compliance 1Osteitis Deformans 1Inflammatory Breast Neoplasms 1Hyperlipidemias 1Hormone-sensitive Metastatic Breast Cancer 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1HER2 Negative Breast Cancer 1Breast Diseases 1Breast Cancer Invasive 1Anatomic Stage I Breast Cancer AJCC v8 1Advanced Metastatic Breast Cancer 1

Interventions

Anastrozole 8exemestane 7Trastuzumab 7Letrozole 7palbociclib 6Docetaxel 6abemaciclib 5Fulvestrant 5ribociclib 4pyrotinib 4entinostat 4Cyclophosphamide 4Tamoxifen 3Doxorubicin 3pertuzumab 2Sodium Chloride 2Paclitaxel 2Lapatinib 2Gonadotropin-Releasing Hormone 2Exercise 2Everolimus 2Epirubicin 2Drug Evaluation 2Capecitabine 2Botulinum Toxins, Type A 2Blood Specimen Collection 2Aromatase Inhibitors 2AZD9833 2tucatinib 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Diseases × Goserelin × Breast × Clear all
NCT03373708 2017-12-18

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

Shandong Cancer Hospital and Institute

Phase 2/3 Unknown
200 enrolled
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡